Alx Oncology Holdings (ALXO) Cash from Operations (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Cash from Operations of 18648000.0 for Q1 2026, up 1.75% sequentially from 18980000.0 in Q4 2025, and up 24.39% YoY from 14991708.19 in Q1 2025.
Alx Oncology Holdings (ALXO) Cash from Operations (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Cash from Operations for 8 years, with the latest figure at 18648000.0 in Q1 2026.
- Quarterly Cash from Operations rose 24.39% year-over-year to 18648000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78127000.0 (up 28.09% YoY) and the FY2025 annual result came in at 84142000.0, up 30.98% from the prior year.
- Cash from Operations advanced to 18648000.0 in Q1 2026 per ALXO's latest filing, from 18980000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 16998000.0 in Q2 2022 and troughed at 39678000.0 in Q4 2023.
- A 5-year average of 26134647.06 and a median of 25376000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 302.61% in 2022, then jumped 40.77% in 2025.
- Over 5 years, Cash from Operations stood at 20668000.0 in 2022, then plunged by 91.98% to 39678000.0 in 2023, then gained by 19.23% to 32046000.0 in 2024, then jumped by 40.77% to 18980000.0 in 2025, then grew by 1.75% to 18648000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 18648000.0, 18980000.0, and 17093000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | -16.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.06 Mn |
| Jun 30, 2026 | -16.06 Mn |
| Mar 31, 2026 | -18.65 Mn |
| Mar 31, 2026 | -18.65 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Sep 30, 2025 | -17.09 Mn |
| Sep 30, 2025 | -17.09 Mn |
| Jun 30, 2025 | -23.41 Mn |
| Jun 30, 2025 | -23.41 Mn |
| Mar 31, 2025 | -24.66 Mn |
| Mar 31, 2025 | -24.66 Mn |
| Dec 31, 2024 | -32.05 Mn |
| Dec 31, 2024 | -32.05 Mn |
| Sep 30, 2024 | -25.38 Mn |
| Sep 30, 2024 | -25.38 Mn |
| Jun 30, 2024 | -26.57 Mn |
| Jun 30, 2024 | -26.57 Mn |
| Mar 31, 2024 | -37.92 Mn |
| Mar 31, 2024 | -37.92 Mn |